Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine

Abstract

The present invention provides a nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof having an inhibitory effect on the production of kynurenine, represented by formula (I):(whereinR6 and R7 may be the same or different and each represent a hydrogen atom or the like,R8, R9, R10, and R11 may be the same or different and each represent a hydrogen atom or the like,R1 represents lower alkyl which may be substituted with cycloalkyl, or the like, andR3 represents optionally substituted aryl or an optionally substituted heterocyclic group).

1 - 20 . (canceled) 
     
     
         21 . A nitrogen-containing heterocyclic compound: 
       
         
           
           
               
               
           
         
       
       or a pharmacologically acceptable salts thereof. 
     
     
         22 . A pharmaceutical composition comprising, as an active ingredient, the nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof of  claim 21 . 
     
     
         23 . A kynurenine production inhibitor comprising, as an active ingredient, the nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof of  claim 21 . 
     
     
         24 . A method for inhibiting the production of kynurenine, comprising a step of administering an effective amount of the nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof of  claim 21 . 
     
     
         25 . A preventive or therapeutic agent for a disease involving the production of kynurenine, comprising, as an active ingredient, the nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof of  claim 21 . 
     
     
         26 . A method for preventing or treating a disease involving the production of kynurenine, comprising a step of administering an effective amount of the nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof of  claim 21 . 
     
     
         27 . A method of producing a pharmaceutical composition for treating for the manufacture of a preventive or therapeutic agent for a disease involving the production of kynurenine comprising, mixing the nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof of  claim 21  with a pharmaceutically acceptable carrier. 
     
     
         28 . The method of  claim 26 , wherein the disease involving the production of kynurenine is selected from the group consisting of cancer (tumor), immune diseases, neurodegenerative diseases, and an infection. 
     
     
         29 . The method of  claim 28 , wherein the disease involving the production of kynurenine is cancer (tumor). 
     
     
         30 . The method of  claim 29 , wherein the cancer (tumor) is selected from the group consisting of a hematopoietic tumor, multiple myeloma, breast cancer, ovarian cancer, endometrial cancer, cervical cancer, prostate cancer, bladder cancer, renal cancer, gastric cancer, esophagus cancer, hepatic cancer, biliary tract cancer, colon cancer, rectal cancer, pancreatic cancer, lung cancer, head and neck cancer, osteosarcoma, melanoma, and brain tumor. 
     
     
         31 . The method of  claim 30 , wherein the cancer (tumor) is a hematopoietic tumor or multiple myeloma. 
     
     
         32 . The method of  claim 28 , wherein the disease involving the production of kynurenine is an infection. 
     
     
         33 . The method of  claim 32 , wherein the infection is selected from the group consisting of a viral infection, bacterial infection, fungal infection, chlamydial infection, and rickettsial infection. 
     
     
         34 . The method of  claim 33 , wherein the infection is a viral infection. 
     
     
         35 . The method of  claim 28 , wherein the disease involving the production of kynurenine is an immune disease.